Document:

Letter Agreement between Optio Software, Inc. and Steve Kaye

 Exhibit 10.5 
  
 December 21, 2004 
  
 Steve Kaye 
 Optio Software, Inc. 
 3015 Windward Plaza 
 Alpharetta, GA 30005 
  
 Dear Mr. Kaye: 
  
 Optio Software, Inc. (the “Company”) considers the establishment and maintenance of a sound and vital management
to be essential to protecting and enhancing the best interests of the Company and its shareholders. In this regard, the Company recognizes that, as is the case with many publicly held corporations, the possibility of a change in control may exist
and that such possibility, and the uncertainty and questions which it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company and its shareholders. Accordingly, the
Company’s Board of Directors has determined that appropriate steps should be taken to reinforce and encourage the continued attention and dedication of members of the Company’s management, including yourself, to their assigned duties
without distraction in the face of the potentially disturbing circumstances arising from the possibility of a change in control of the Company. 
  
 In order to induce you to remain in the employ of the Company, this letter agreement sets forth the severance benefits which the Company agrees will be
provided to you in the event your employment with the Company is terminated in connection with a “Change of Control” (as defined in paragraph 2 hereof) under the circumstances described below. 
  
 1. TERM. This Agreement shall commence on the date hereof and
shall continue for so long as you remain as an employee/officer of the Company. In the event of a Change of Control your rights thereafter under this Agreement shall become permanent, are not terminable, and cannot be affected by any corporate
action without your consent, except as is provided for in paragraph 3 of this Agreement with respect to death or normal retirement, termination by the Company for cause, or your disability. 
  
 2. CHANGE IN CONTROL. No benefits shall be payable hereunder
unless there shall have been a Change of Control and your employment by the Company shall have been terminated in accordance with paragraph 3 below. For purposes of this Agreement, a “Change of Control” shall be deemed to have occurred
upon the occurrence of one of the following events: 
  
 (i) the
acquisition, directly or indirectly after the date of this Agreement, in one series of related transactions, of 45% or more of the Company’s common stock by any “person” as that term is defined in Section 13(d)(3) of the Securities
Exchange Act of 1934, as amended excluding any acquisitions in capital raising transactions; 

 (ii) the consummation of a merger, consolidation, share exchange or similar transaction of the Company
with any other corporation, entity or group, as a result of which the holders of the voting capital stock of the Company as a group would receive less than 45% of the voting capital stock of the surviving or resulting corporation, or 
  
 (iii) the consummation of an agreement providing for the sale or transfer
(other than as security for obligations of the Company) of substantially all the assets of the Company; 
  
 provided that none of the transactions described in subsections (i), (ii) or (iii) shall include a transaction or series of transactions with an entity
which is controlled, directly or indirectly, after the transaction, by the Company or another entity in which the shareholders of the Company immediately prior to such transaction control, directly or indirectly, at least 45% of the outstanding
voting securities (including any entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries). 
  
 3. TERMINATION FOLLOWING CHANGE IN CONTROL. If any of the
events described in paragraph 2 hereof constituting a Change of Control shall occur, you shall be entitled to the benefits provided in paragraph 4 hereof upon the termination of your employment, immediately before or within twelve (12) months
following the Change of Control. Notwithstanding the foregoing to the contrary, immediately upon a Change of Control, the Company and your individual performance targets for the Annual Bonus Incentive Plan shall be deemed to be met in full for the
remainder plan year in which the Change of Control occurs. Payment of such bonus shall be made to you on the earlier of (i) your termination pursuant to this paragraph 3, or (ii) in accordance with the payment schedule set forth in the bonus plan.
In the event your employment with the Company is terminated for any reason and subsequently a Change of Control shall have occurred, you shall not be entitled to any benefits nor have any rights hereunder. 
  
 (i) Disability; Retirement. 
  
 (A) If, as a result of your incapacity due to physical or mental illness,
you have been absent from your duties with the Company on a full-time basis for 180 consecutive days and such period of absence commenced prior to a Change in Control of the Company, the Company may give you at least thirty (30) days prior written
notice of termination of this Agreement and if you shall not have returned to the full-time performance of your duties by the date of termination specified in such notice, the Company may terminate this Agreement for “Disability.”

  
 (B) Termination by the Company or by you of your employment
based on “Retirement” shall mean termination in accordance with the Company’s retirement policy, including early retirement, generally applicable to its salaried employees or in accordance with any retirement arrangement established
with your consent with respect to you. 
  
 (ii)
Cause. The Company may terminate your employment for cause. For the purposes of this Agreement, the Company shall have “Cause” to terminate your employment hereunder upon (A) your material breach of this agreement, provided
that, if such breach is curable, you shall be entitled to written notice and a thirty (30) day opportunity to cure such breach; (B) any act or omission by you which is, or is likely to be, materially injurious to the Company or the business
reputation of the Company; (C) your dishonesty, fraud, malfeasance, gross negligence or misconduct in the performance of your duties or otherwise having an adverse affect on the Company; (D) your continued failure to satisfactorily perform your
duties, to follow the direction (consistent with your duties) of the individual to whom you report, or to follow the policies, procedures, and rules of the Company, after notice and a thirty (30) day opportunity to cure; (E) your arrest, indictment
for, or conviction of, or your entry of a plea of guilty or no contest to, a felony or crime involving moral turpitude; or (F) your resignation for other than Good Reason. 
  

 - 2 - 

 (iii) Good Reason. You may terminate your employment for Good Reason. For purposes of this
Agreement “Good Reason” shall mean the occurrence after a Change of Control, without your written consent, (except as provided in paragraph 3 with respect to certain events occurring prior to a Change of Control) of any of the following
circumstances: 
  
 (A) the Company takes any action which is
inconsistent with, or results in the reduction of, your then current title, duties or responsibilities immediately prior to a Change of Control; 
  
 (B) the Company reduces your then current base salary; 
  
 (C) the Company’s requiring you to relocate more than seventy-five (75) miles from the location of the offices at which you are principally employed
immediately prior to the date of a Change of Control; 
  
 (D) the
Company reduces the benefits to which you are entitled at the time of a Change of Control, unless a similar reduction is made for other executive employees; or 
  

(E) the failure of the Company to obtain the assumption of the agreement to perform this Agreement by any successor as contemplated in paragraph 5
hereof. 
  
 Good Reason shall not include any isolated,
insubstantial or inadvertent action that (i) is not taken in bad faith, and (ii) is remedied by the Company within thirty (30) days of receiving notice by you of such action. 
  
 4. COMPENSATION UPON TERMINATION OR DURING DISABILITY FOLLOWING A CHANGE OF CONTROL; OPTIONS 
  
 (a) If your employment is terminated in connection with a Change of Control,
then the following provisions shall apply: 
  
 (i) During any
period that you fail to perform your duties hereunder as a result of Disability, you shall continue to receive your full base salary at the rate then in effect and any other compensation then payable to you until this Agreement is terminated
pursuant to paragraph 3(i) hereof. Thereafter, you benefits shall be determined in accordance with the Company’s disability plan then in effect. 
  
 (ii) If your employment shall be terminated for Cause, the Company shall pay you your full base salary through the date of your termination at the rate in
effect at such time, plus all other amounts to which you are entitled under any compensation or benefit plan of the Company at the time such payments are due, and the Company shall have no further obligation to you under this Agreement. 

 
 (iii) If the Company shall terminate your employment other than pursuant
to paragraph 3(i) or 3(ii) hereof or if you shall terminate your employment for Good Reason pursuant to paragraph 3(iii) hereof, then the Company shall: 
  
 (A) pay to you a separation payment equal to six (6) months of your base salary in effect as of the date of your termination, payable in accordance with
the Company’s normal payroll practices (or at the election of the Company, payable as a lump sum payment); 
  
 (B) pay to you any earned but unpaid cash bonus amount as described in paragraph 3 above; and 
  

 - 3 - 

 (C) maintain in full force and effect for the continued benefit of you and your dependants until the
earlier of six (6) months following the date of your termination, the equivalent of all life, disability, accident, health insurance and other employee benefit plans, programs, benefits or arrangements in which you were entitled to participate
immediately prior to the date of termination provided that your continued participation is possible under the general terms and provisions of such plans and programs. In the event that your participation in any such plan or program is barred, the
Company shall arrange to provide you with benefits substantially similar to those which you were entitled to receive under such plans and programs immediately prior to your termination, provided that any reduction of benefits which constituted a
basis for your termination of employment for Good Reason pursuant to subparagraph 3(ii) shall not be taken into account for purposes of determining your continued benefits under this subparagraph 4(iii). Notwithstanding the foregoing, the Company
shall not provide a benefit otherwise receivable by you pursuant to this paragraph (iii) during any period in which an equivalent benefit is actually provided to you following your termination, and you must report to the Company any such benefit
actually received by you. 
  
 (iv) Except as provided in
subparagraph 4(iii)(C), you shall not be required to mitigate the amount of any payment provided for in this paragraph 4 by seeking other employment or otherwise, nor shall the amount of any payment provided for in this paragraph 4 be reduced by any
compensation earned by you as the result of employment by another employer after the date of your termination, or otherwise. 
  
 (b) Upon a Change in Control, all unvested options held by you shall vest in full immediately upon and in conjunction with the consummation of the
transaction involving the Change in Control. 
  
 5.
RESTRICTIVE COVENANTS. You acknowledge that the restrictions contained in this Section 5 are reasonable and necessary to protect the legitimate business interests of the Company, and will not impair or infringe upon your right to
work or earn a living after your employment with the Company ends. 
  
 A. Trade Secrets and Confidential Information. You represent and warrant that: (i) you are not subject to any agreement that would prevent
you from performing your duties for the Company or otherwise complying with this Agreement, and (ii) you are not subject to or in breach of any non-disclosure agreement, including any agreement concerning trade secrets or confidential information
owned by any other party. 
  
 You agree that you
will not: (i) use, disclose, or reverse engineer the Trade Secrets or the Confidential Information, except as authorized by the Company; (ii) during your employment with the Company, use, disclose, or reverse engineer (a) any confidential
information or trade secrets of any former employer or third party, or (b) any works of authorship developed in whole or in part by you during any former employment or for any other party, unless authorized in writing by the former employer or third
party; or (iii) upon your resignation or termination (a) retain Trade Secrets or Confidential Information, including any copies existing in any form (including electronic form), which are in your possession or control, or (b) destroy, delete, or
alter the Trade Secrets or Confidential Information without the Company’s consent. 
  
 The obligations under this Section 5A shall: (i) with regard to the Trade Secrets, remain in effect as long as the information constitutes
a trade secret under applicable law, and (ii) with regard to the Confidential Information, remain in effect during the Restricted Period. 
  
 B. Non-Solicitation of Customers. During the Restricted Period, you will not solicit any Customer of the Company for the purpose of
providing any goods or services competitive with the Business. The restrictions set forth in this Section 5B apply only to the Customers with whom you had Contact. 
  

 - 4 - 

 C. Non-Recruit of Employees. During the Restricted Period, you will not, directly or
indirectly, solicit, recruit or induce any Employee to (a) terminate his or her employment relationship with the Company or (b) work for any other person or entity engaged in the Business. 
  
 D. Work Product. Your employment duties may include
inventing in areas directly or indirectly related to the business of the Company or to a line of business that the Company may reasonably be interested in pursuing. All Work Product shall constitute work made for hire. If (i) any of the Work Product
may not be considered work made for hire, or (ii) ownership of all right, title, and interest to the legal rights in and to the Work Product will not vest exclusively in the Company, then, without further consideration, you assign all
presently-existing Work Product to the Company, and agree to assign, and automatically assign, all future Work Product to the Company. 
  
 The Company will have the right to obtain and hold in its own name copyrights, patents, design registrations, proprietary database rights,
trademarks, rights of publicity, and any other protection available in the Work Product. At the Company’s request, you agree to perform, during or after your employment with the Company, any acts to transfer, perfect and defend the
Company’s ownership of the Work Product, including, but not limited to: (i) executing all documents (including a formal assignment to the Company) necessary for filing an application or registration for protection of the Work Product (an
“Application”), (ii) explaining the nature of the Work Product to persons designated by the Company, (iii) reviewing Applications and other related papers, or (iv) providing any other assistance reasonably required for the orderly
prosecution of Applications. 
  
 You agree to
provide the Company with a written description of any Work Product in which you are involved (solely or jointly with others) and the circumstances surrounding the creation of such Work Product. 
  
 E. License. You grant to the Company an irrevocable,
nonexclusive, worldwide, royalty-free license to: (i) make, use, sell, copy, perform, display, distribute, or otherwise utilize copies of the Licensed Materials, (ii) prepare, use and distribute derivative works based upon the Licensed Materials,
and (ii) authorize others to do the same. You shall notify the Company in writing of any Licensed Materials you deliver to the Company. 
  
 F. Release. You consent to the Company’s use of your image, likeness, voice, or other characteristics in the Company’s products
or services. You release the Company from any claims which you have or may have for right of publicity, copyright infringement, or any other causes of action arising out of the use, distribution, adaptation, reproduction, broadcast, or exhibition of
such characteristics. 
  
 G. Post-Employment
Disclosure. During the Restricted Period, you will disclose that you have covenants (and the nature of those covenants) to persons and/or entities to whom you provide goods and services. If, during the Restricted Period, you provide services to
another person or entity which provides goods or services competitive with the goods or services provided by the Company you shall provide the Company with such person or entity’s name, your job title, and a description of the services you will
provide. 
  
 H. Injunctive Relief. You agree that
if you breach paragraph 5 of this Agreement: (i) the Company would suffer irreparable harm; (ii) it would be difficult to determine damages, and money damages alone would be an inadequate remedy for the injuries suffered by the Company, and (iii) if
the Company seeks injunctive relief to enforce this Agreement, you will waive and will not (a) assert any defense that the Company has an adequate remedy at law with respect to the breach, or (b) require that the Company submit proof of the economic
value of any Trade Secret or Confidential Information. Nothing contained in this Agreement shall limit the Company’s right to any other remedies at law or in equity. 
  

 - 5 - 

 6. SEVERABILITY. The provisions of this Agreement are severable. If any provision is
determined to be invalid, illegal, or unenforceable, in whole or in part, the remaining provisions and any partially enforceable provisions shall remain in full force and effect.  
  
 7. ATTORNEYS’ FEES. In the event of litigation relating to
this Agreement, the prevailing party shall be entitled to recover attorneys’ fees and costs of litigation in addition to all other remedies available at law or in equity.  
  
 8. SURVIVAL; SUCCESSORS AND ASSIGNS. This Agreement shall be
assignable to, and shall inure to the benefit of, the Company’s successors and assigns, including, without limitation, successors through merger, name change, consolidation, or sale of a majority of the Company’s stock or assets, and shall
be binding upon you. A Change of Control shall not affect the terms of this Agreement. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid or
otherwise. You shall not have the right to assign your rights or obligations under this Agreement. The covenants contained in paragraph 5 of this Agreement shall survive cessation of your employment with the Company, regardless of the reason for
cessation of your employment and regardless of who causes the cessation.  
  
 9. NOTICE. For the purposes of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or
mailed by United States registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth on the first page of this Agreement, provided that all notices to the Company shall be directed to the attention of
the Chief Executive Officer of the Company with a copy to the Secretary of the Company, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be
effective only upon receipt. 
  
 10.
MISCELLANEOUS. No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by you and such officer as may be specifically designated by the Board of
Directors of the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of
similar or dissimilar provisions or conditions at the same or at any time prior to subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party
which are not set forth expressly in this Agreement. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Georgia. Any payments provided for hereunder shall be paid net of any
applicable withholding required under foreign, federal, state or local law. The obligations of the Company under paragraphs 4 and 5 shall survive the expiration of the term of this Agreement, with respect to paragraph 4, to the extent benefits
become due and owing under such provisions and, with respect to paragraph 5, to the extent the Company continues to have obligations under this Agreement. 
  
 11. ENTIRE AGREEMENT. This Agreement sets forth the entire agreement of the parties hereto with respect to severance benefits payable
to you after a Change of Control, and during the terms of the Agreement supersedes the provisions of all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer,
employee or representative of any party hereto with respect to such subject matter. 
  

 - 6 - 

 12. EMPLOYMENT. This Agreement shall not be deemed to be an employment agreement for a
specific term and nothing herein shall change your status as an “employee at will”; except in connection with a “Change in Control” and then only as set forth herein. 
  
 13. DEFINITIONS. 
  
 A. “Business” shall mean the business of (i) developing and providing software that enables a business to integrate and present information to
its customers, suppliers, partners, and employees through various types of media (including, but not limited to, print, Internet, e-mail and fax) by customizing, delivering and exchanging information over a computer network (the
“Software”), and (ii) providing the implementation, training, and consulting services that support the Software. 
  
 B. “Confidential Information” means information of the Company, to the extent not considered a Trade Secret under applicable law, that (i)
relates to the business of the Company, (ii) possesses an element of value to the Company, (iii) is not generally known to the Company’s competitors, and (iv) would damage the Company if disclosed. Confidential Information includes, but is not
limited to, (i) future business plans, (ii) the composition, description, schematic or design of products, future products or equipment of the Company, (iii) communication systems, audio systems, system designs and related documentation, (iv)
advertising or marketing plans, (v) information regarding independent contractors, employees, clients and customers of the Company, and (vi) information concerning the Company’s financial structure and methods and procedures of operation.
Confidential Information shall not include any information that (i) is or becomes generally available to the public other than as a result of an unauthorized disclosure, (ii) has been independently developed and disclosed by others without violating
this Agreement or the legal rights of any party, or (iii) otherwise enters the public domain through lawful means. 
  
 C. “Contact” means any interaction between you and a Customer which (i) takes place in an effort to establish, maintain, and/or further a
business relationship on behalf of the Company and (ii) occurs during the last year of your employment with the Company (or during your employment if employed less than a year). 
  
 D. “Customer” means any person or entity to whom the Company has sold its products or services, or solicited to
sell its products or services. 
  
 E. “Employee” means
any person who (i) is employed by the Company at the time your employment with the Company ends, (ii) was employed by the Company during the last year of your employment with the Company (or during your employment if employed less than a year), or
(iii) is employed by the Company during the Restricted Period. 
  
 F. “Licensed Materials” means any materials that you utilize for the benefit of the Company, or deliver to the Company or the Company’s customers, which (i) do not constitute Work Product, (ii) are created by you or of which
you are otherwise in lawful possession, and (iii) you may lawfully utilize for the benefit of, or distribute to, the Company or the Company’s customers. 
  
 G. “Restricted Period” means the time period during your employment with the Company, and for one year after your employment with the Company
ends. 
  
 H. “Trade Secrets” means information of the
Company, and its licensors, suppliers, clients and customers, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a
process, financial data, financial plans, product plans, or a list of actual or potential customers or suppliers which is not commonly known by or available to the public and which information (i) derives economic value, actual or potential, from

  

 - 7 - 

 
not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use,
and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. 
  
 I. “Work Product” means (a) any data, databases, materials, documentation, computer programs, inventions (whether or not patentable), designs,
and/or works of authorship, including but not limited to, discoveries, ideas, concepts, properties, formulas, compositions, methods, programs, procedures, systems, techniques, products, improvements, innovations, writings, pictures, audio, video,
images of you, and artistic works, and (b) any subject matter protected under patent, copyright, proprietary database, trademark, trade secret, rights of publicity, confidential information, or other property rights, including all worldwide rights
therein, that is or was conceived, created or developed in whole or in part by you while employed by the Company and that either (i) is created within the scope of your employment, (ii) is based on, results from, or is suggested by any work
performed within the scope of your employment and is directly or indirectly related to the business of the Company or a line of business that the Company may reasonably be interested in pursuing, (iii) has been or will be paid for by the Company, or
(iv) was created or improved in whole or in part by using the Company’s time, resources, data, facilities, or equipment. 
  
 [signature confirmed on next page] 
  

 - 8 - 

 If this letter correctly sets forth our agreement on the subject matter hereof, kindly sign and return to
the Company the enclosed copy of this letter which will then constitute our agreement on this matter. 
  

			
	Sincerely,
	
	OPTIO SOFTWARE, INC.
		
	By:	 	 /s/ C. WAYNE CAPE

	 	 	C. Wayne Cape
	 	 	President and Chief Executive Officer

  
 Agreed to this 27th day
of December, 2004. 
  

	
	 /s/ Steve Kaye

	 Employee

  

 - 9 -Purchase Agreement dated December 21, 2004

  
 Exhibit 10.1

  
 PURCHASE AGREEMENT 
  
 THIS PURCHASE AGREEMENT (“Agreement”) is made as of the
21st day of December, 2004 by and among Velocity Express Corporation, a Delaware corporation (the
“Company”), and the Investors set forth on the signature pages affixed hereto (each an “Investor” and collectively the “Investors”). 
  
 Recitals 
  
 A. The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the
provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended; and 
  
 B. The Investors wish to purchase from the Company, and the Company wishes to
sell and issue to the Investors, upon the terms and conditions stated in this Agreement, an aggregate of $21,000,000 in face amount of the Company’s Convertible Notes in the form of Exhibit A hereto (the “Notes”); and

  
 C. Upon approval of the Proposals (as defined below) and the
satisfaction of certain other conditions, the Notes will automatically convert into shares of Series M Convertible Preferred Stock, par value $0.004 per share (the “Preferred Stock”), such Preferred Stock to have the relative rights,
preferences and designations set forth in the Certificate of Designation of Preferences and Rights of Series M Convertible Preferred Stock set forth in Exhibit B hereto (the “Certificate of Designations”); and 
  
 C. Contemporaneous with the sale of the Notes, the parties hereto will
execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights under the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, and applicable state securities laws. 
  
 In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows: 
  
 1.
Definitions. In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth below: 
  
 “Affiliate” means, with respect to any
Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common control with, such Person. 
  

 “Business Day” means a day, other than a Saturday or Sunday, on which
banks in New York City are open for the general transaction of business. 
  
 “Capital Increase” has the meaning set forth in Section 7.9. 
  
 “Common Stock” means the common stock, par value $0.004 per share, of the Company and any securities into which the
Common Stock may hereafter be reclassified. 
  
 “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
  
 “Company’s Knowledge” means the actual knowledge of the executive officers (as defined
in Rule 405 under the 1933 Act) of the Company, after due inquiry. 
  
 “Confidential Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae, compositions, processes, procedures and techniques, research and
development information, computer program code, performance specifications, support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information). 
  
 “Consents and Waivers” means the consents
and waivers provided by the holders of Senior Debt in the form attached hereto as Exhibit D. 
  
 “Control” (including the terms “controlling,” “controlled by” or “under common control
with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 
  
 “Conversion Date” means the date that the
conversion of the Notes into Shares is effective pursuant to the terms of the Notes. 
  
 “Conversion Shares” means the shares of Common Stock issuable upon conversion of the Shares and the PIK Shares.

  
 “Effective Date” means the
date on which the initial Registration Statement is declared effective by the SEC. 
  
 “Effectiveness Deadline” means the date on which the initial Registration Statement is required to be declared effective
by the SEC under the terms of the Registration Rights Agreement. 
  
 “Intellectual Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or not patentable and whether or not reduced to 

  

 -2- 

 
practice); (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill
associated with each of the foregoing; (iii) copyrights and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software (including but not limited to data, data bases and
documentation). 
  
 “Material Adverse
Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the
Company to perform its obligations under the Transaction Documents. 
  
 “Nasdaq” means The Nasdaq Stock Market, Inc. 
  
 “Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 
  
 “PIK Shares” means shares of Preferred Stock issued as pay-in-kind dividends on the Shares
or any previously issued PIK Shares. 
  
 “Proposals” has the meaning set forth in Section 7.9. 
  
 “Purchase Price” means Twenty-One Million Dollars ($21,000,000). 
  
 “Registration Statement” has the meaning
set forth in the Registration Rights Agreement. 
  
 “Reverse Split” means a reverse split of the Common Stock as determined by the Company’s Board of Directors in the good faith exercise of its business judgment which would achieve, immediately after giving effect
thereto, a per share market price of at least $4.00, but in any event no less than one-for-50. 
  
 “SEC Filings” has the meaning set forth in Section 4.6. 
  
 “Securities” means the Notes, the Shares, the PIK Shares and the Conversion Shares.

  
 “Security Agreement” means
the Security Agreement among the Company and the Investors in the form of Exhibit E attached hereto. 
  
 “Senior Debt” means the indebtedness outstanding under (i) the Amended and Restated Loan and Security Agreement, dated as
of November 26, 2003, among the Company, the Subsidiaries named therein, Fleet Capital Corporation, Merrill Lynch Capital and the other lenders named therein, as amended as of the date hereof, and (ii) the Note Purchase Agreement, 

  

 -3- 

 
dated as of November 26, 2003, among the Company, Velocity Express, Inc. and BET Associates, L.P., as amended as of the date hereof. 
  
 “Shares” means the shares of Preferred
Stock issuable to the Investors upon the conversion of the Notes. 
  
 “SSF” means Special Situations Fund III, L.P. and its Affiliates. 
  
 “Subsidiary” of any Person means another Person, an amount of the voting securities, other voting ownership or voting
partnership interests of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by
such first Person. 
  
 “Transaction
Documents” means this Agreement, the Notes, the Security Agreement, the Certificate of Designations, the Registration Rights Agreement, the Voting Agreements and the Consents and Waivers. 
  
 “Voting Agreement” means the Voting
Agreement to be entered into among the Company, the Investors and the other parties thereto, the form of which is attached hereto as Exhibit F. 
  
 “1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations
promulgated thereunder. 
  
 “1934
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder. 
  
 2. Purchase and Sale of the Notes. Subject to the terms and conditions of this Agreement, on the Closing Date, each of the Investors shall
severally, and not jointly, purchase, and the Company shall sell and issue to the Investors, the Notes at 100% of face value in the respective amounts set forth opposite the Investors’ names on the signature pages attached hereto in exchange
for the Purchase Price as specified in Section 3 below. 
  
 3.
Closing. (a) Upon confirmation that the other conditions to closing specified herein have been satisfied or duly waived by the Investors, the Company shall deliver to Lowenstein Sandler PC, in trust, the Notes, registered in such name or
names as the Investors may designate with instructions that the Notes certificates are to be held for release to the Investors only upon payment in full of the Purchase Price to the Company by all the Investors. Upon such receipt by counsel to SSF
of the Notes, each Investor shall promptly, but no more than one Business Day thereafter, cause a wire transfer in same day funds to be sent to the account of the Company as instructed in writing by the Company, in an amount representing such
Investor’s pro rata portion of the Purchase Price as set forth on the signature pages to this Agreement. On the date (the “Closing Date”) the Company receives the Purchase Price, the Notes shall be released to the Investors (the
“Closing”). The Closing of the purchase and sale of 

  

 -4- 

 
the Notes shall take place at the offices of counsel to SSF, or at such other location and on such other date as the Company and the Investors shall mutually
agree. 
  
 (b) The Company may sell up to
$2,000,000 in additional principal amount of the Notes under the terms of this Agreement for up to 30 days after the Closing Date. By execution of a counterpart of this Agreement, a purchaser of any such additional Notes shall be deemed to be an
“Investor” for all purposes hereof and the term “Notes” shall include any such additional Notes for all purposes herein. 
  
 4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors that, except as set forth in the
schedules delivered herewith (collectively, the “Disclosure Schedules”): 
  
 4.1 Organization, Good Standing and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties. Each of the Company and its
Subsidiaries is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the
failure to so qualify has not and could not reasonably be expected to have a Material Adverse Effect. The Company’s Subsidiaries are listed on Schedule 4.1 hereto. 
  
 4.2 Authorization. The Company has full power and authority and, except for approval of the Proposals
by its stockholders as contemplated in Section 7.9 and the amendment of the Company’s Certificate of Incorporation contemplated by adoption of such Proposals, has taken all requisite action on the part of the Company, its officers, directors
and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) authorization of the performance of all obligations of the Company hereunder or thereunder (including effecting the Reverse Split and the
Capital Increase), and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms, subject to (i) bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and (ii) laws relating to the
availability of specific performance, injunctive relief or other equitable remedies. 
  
 4.3 Capitalization. Schedule 4.3 sets forth, on a pro forma basis after giving effect to the adoption of the Proposals,
effecting the Capital Increase, and the transactions contemplated by the Transaction Documents, but prior to the Reverse Split, (a) the authorized capital stock of the Company on the date hereof; (b) the number of shares of capital stock issued and
outstanding; (c) the number of shares of capital stock issuable pursuant to the Company’s stock plans; and (d) the number of shares of capital stock issuable and reserved for issuance pursuant to securities (other than the Shares, the PIK
Shares and the Conversion Shares) exercisable for, or convertible into or exchangeable for any shares of capital stock of the Company. Excluding shares of the Company’s Series I Preferred Stock, Series J Preferred Stock 

  

 -5- 

 
and Series K Preferred Stock, the issuance of which requires stockholder approval as described on Schedule 4.3, all of the issued and outstanding shares of
the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights and were issued in full compliance with applicable state and federal securities law and any rights of
third parties. Except as described on Schedule 4.3, all of the issued and outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights,
were issued in full compliance with applicable state and federal securities law and any rights of third parties and are owned by the Company, beneficially and of record, subject to no lien, encumbrance or other adverse claim. Except as described on
Schedule 4.3, no Person is entitled to pre-emptive or similar statutory or contractual rights with respect to any securities of the Company. Except as described on Schedule 4.3, there are no outstanding warrants, options, convertible
securities or other rights, agreements or arrangements of any character under which the Company or any of its Subsidiaries is or may be obligated to issue any equity securities of any kind and except as contemplated by this Agreement, neither the
Company nor any of its Subsidiaries is currently in negotiations for the issuance of any equity securities of any kind. Except as described on Schedule 4.3 and except for the Registration Rights Agreement and the Voting Agreement, there are
no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. Except as
described on Schedule 4.3 and except as provided in the Registration Rights Agreement, no Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection
with the registration of securities of the Company for its own account or for the account of any other Person. 
  
 Except as described on Schedule 4.3, the issuance and sale of the Securities hereunder will not obligate the Company to issue
shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. 
  
 Except as described on Schedule 4.3, the Company does
not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 
  
 4.4 Valid Issuance. Upon the conversion of the Notes
in accordance with their terms, the Shares will be duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, shall be free and clear of all encumbrances and
restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws, and will be entitled to the relative rights, powers and preferences set
forth in the Certificate of Designations. Upon the conversion of the Notes in accordance with their terms, the PIK Shares will be duly and validly authorized and, when issued pursuant to the terms of the Certificate of Designations, will be validly
issued, fully paid and nonassessable, shall be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable

  

 -6- 

 
securities laws, and will be entitled to the relative rights, powers and preferences set forth in the Certificate of Designations. Upon the conversion of the
Shares and/or the PIK Shares, the Conversion Shares will be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by
applicable securities laws and except for those created by the Investors. Upon stockholder approval of the Proposals described in Section 7.9 and the amendments to the Company’s Certificate of Incorporation contemplated by adoption of such
Proposals, the Company will have reserved a sufficient number of shares of Common Stock for the issuance of the Conversion Shares, free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction
Documents or imposed by applicable securities laws and except for those created by the Investors. 
  
 4.5 Consents. Except for approval of the Proposals by its stockholders as contemplated in Section 7.9, the execution, delivery and
performance by the Company of the Transaction Documents and the offer, issuance and sale of the Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than (i) filings
that have been made pursuant to applicable state securities laws, (ii) post-sale filings pursuant to applicable state and federal securities laws and (iii) the filing of a Listing of Additional Shares notification with Nasdaq relating to the
Conversion Shares, which the Company undertakes to file within the applicable time periods. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to
exempt (i) the issuance and sale of the Notes, (ii) the issuance of the Shares upon the due conversion of the Notes, (iii) the issuance of the PIK Shares in accordance with the Certificate of Designations, (iv) the issuance of the Conversion Shares
upon due conversion of the Shares and the PIK Shares, and (v) the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other “poison pill” arrangement, any anti-takeover,
business combination or control share law or statute binding on the Company or to which the Company or any of its assets and properties may be subject and any provision of the Company’s Certificate of Incorporation or By-laws that is or could
reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without limitation, the issuance of the Securities and the ownership, disposition or voting of the Securities by the
Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents. 
  
 4.6 Delivery of SEC Filings; Business. The Company has made available to the Investors through the EDGAR system, true and complete
copies of the Company’s Annual Report on Form 10-K for the fiscal year ended June 28, 2003 (the “10-K”), and all other reports filed by the Company pursuant to the 1934 Act since the filing of the 10-K and prior to the date hereof
(collectively, the “SEC Filings”). The Company’s draft Form 10-K for the fiscal year ended July 3, 2004, attached hereto as Exhibit G (the “Draft 10-K”), contains a complete and accurate description in all material
respects of the business of the Company and its Subsidiaries. Except as described on Schedule 4.6, the SEC Filings are the only filings required of the Company pursuant to the 1934 Act for such period. The Company and its Subsidiaries are
engaged in all material respects only in the business described in the SEC Filings and the SEC Filings contain a complete and accurate description in all material respects of the business of the Company and its Subsidiaries. 
  

 -7- 

 4.7 Use of Proceeds. The net proceeds of the sale of the Notes hereunder shall be
used by the Company for working capital and general corporate purposes in accordance with financial budgets approved from time to time by the Board of Directors of the Company. 
  
 4.8 No Material Adverse Change. Since June 28, 2003, except for the transactions contemplated by the
Transaction Documents (including the Reverse Split and the Capital Increase) and except as identified and described in the Draft 10-K or the SEC Filings or as described on Schedule 4.8, there has not been: 
  
 (i) any change in the consolidated assets, liabilities,
financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 27, 2004, except for changes in the ordinary course of
business which have not and could not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 
  
 (ii) any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the
Company, or any redemption or repurchase of any securities of the Company; 
  
 (iii) any material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company or its Subsidiaries; 
  
 (iv) any waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material
right or of a material debt owed to it; 
  
 (v)
any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a Subsidiary, except in the ordinary course of business and which is not material to the assets, properties, financial condition,
operating results or business of the Company and its Subsidiaries taken as a whole (as such business is presently conducted and as it is proposed to be conducted); 
  
 (vi) any change or amendment to the Company’s Certificate of Incorporation or By-laws, or material
change to any material contract or arrangement by which the Company or any Subsidiary is bound or to which any of their respective assets or properties is subject; 
  
 (vii) any material labor difficulties or labor union organizing activities with respect to employees of the
Company or any Subsidiary; 
  
 (viii) any
material transaction entered into by the Company or a Subsidiary other than in the ordinary course of business; 
  
 (ix) the loss of the services of any key employee, or material change in the composition or duties of the senior management of the Company
or any Subsidiary; 
  

 -8- 

 (x) the loss or threatened loss of any customer which has had or could reasonably be
expected to have a Material Adverse Effect; or 
  
 (xi) any other event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect. 
  
 4.9 SEC Filings. 
  
 (a) Except as described in Schedule 4.9, at the time of filing thereof, the SEC Filings complied as to form in all material
respects with the requirements of the 1934 Act and did not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they
were made, not misleading. 
  
 (b) Each
registration statement and any amendment thereto filed by the Company and which has become effective since January 1, 2001 pursuant to the 1933 Act and the rules and regulations thereunder, as of the date such statement or amendment became
effective, complied as to form in all material respects with the 1933 Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made
therein not misleading; and each prospectus filed pursuant to Rule 424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities pursuant thereto did not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. 
  
 4.10 No Conflict, Breach, Violation or Default.
Subject to the stockholder approval of the Proposals described in Section 7.9 and the amendment of the Company’s Certificate of Incorporation contemplated by the adoption of such Proposals, the execution, delivery and performance of the
Transaction Documents by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Certificate of
Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the EDGAR system), or (ii)(a) any statute, rule, regulation or order of any
governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets or properties, or (b) any agreement or instrument to which the Company or any Subsidiary is a party
or by which the Company or a Subsidiary is bound or to which any of their respective assets or properties is subject. 
  
 4.11 Tax Matters. Except as described in Schedule 4.11, the Company and each Subsidiary has timely prepared and filed all
tax returns required to have been filed by the Company or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of the Company in
respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company or any Subsidiary nor, to the 

  

 -9- 

 
Company’s Knowledge, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any federal, state
or local taxing authority except for any assessment which is not material to the Company and its Subsidiaries, taken as a whole. All taxes and other assessments and levies that the Company or any Subsidiary is required to withhold or to collect for
payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending or, to the Company’s Knowledge, threatened against the Company or any Subsidiary or any
of their respective assets or property. Except as described on Schedule 4.11, there are no outstanding tax sharing agreements or other such arrangements between the Company and any Subsidiary or other corporation or entity. 
  
 4.12 Title to Properties. Except as disclosed in the
SEC Filings and except for liens, encumbrances and defects that arise in the ordinary course of business and do not impair the Company’s ownership or use of such properties, the Company and each Subsidiary has good and marketable title to all
real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof
by them; and except as disclosed in the SEC Filings, the Company and each Subsidiary holds any leased real or personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently
planned to be made thereof by them. 
  
 4.13
Certificates, Authorities and Permits. The Company and each Subsidiary possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, and
neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, could reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate. 
  
 4.14 Labor Matters. 
  
 (a) The Company has complied with the federal Worker Adjustment and Retraining Notification Act of 1988, as amended, in connection with
the transactions contemplated by this Agreement and the Transaction Documents. 
  
 (b) Except as set forth on Schedule 4.14, the Company is not a party to or bound by any collective bargaining agreements or other
agreements with labor organizations. The Company has not violated in any material respect any laws, regulations, orders or contract terms, affecting the collective bargaining rights of employees, labor organizations or any laws, regulations or
orders affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours. 
  
 (c) (i) There are no labor disputes existing, or to the Company’s Knowledge, threatened, involving strikes, slow-downs, work
stoppages, job actions, disputes, lockouts or any other disruptions of or by the Company’s employees, (ii) there are no unfair labor practices or petitions for election pending or, to the Company’s Knowledge, threatened before the National

  

 -10- 

 
Labor Relations Board or any other federal, state or local labor commission relating to the Company’s employees, (iii) no demand for recognition or
certification heretofore made by any labor organization or group of employees is pending with respect to the Company and (iv) to the Company’s Knowledge, the Company enjoys good labor and employee relations with its employees and labor
organizations. 
  
 (d) The Company is, and at all
times has been, in full compliance in all material respects with all applicable laws respecting employment (including laws relating to classification of employees and independent contractors) and employment practices, terms and conditions of
employment, wages and hours, and immigration and naturalization. There no claims are pending against the Company before the Equal Employment Opportunity Commission or any other administrative body or in any court asserting any violation of Title VII
of the Civil Rights Act of 1964, the Age Discrimination Act of 1967, 42 U.S.C. §§ 1981 or 1983 or any other federal, state or local Law, statute or ordinance barring discrimination in employment. 
  
 (e) The Company is not a party to, or bound by, any
employment or other contract or agreement that contains any severance, termination pay or change of control liability or obligation, including, without limitation, any “excess parachute payment,” as defined in Section 2806(b) of the
Internal Revenue Code. 
  
 (f) Except as
specified in Schedule 4.14, each of the Company’s employees is a Person who is either a United States citizen or a permanent resident entitled to work in the United States. To the Company’s Knowledge, the Company has no liability
for the improper classification by the Company of such employees as independent contractors or leased employees prior to the Closing. 
  
 4.15 Intellectual Property. 
  
 (a) All Intellectual Property of the Company and its Subsidiaries is currently in compliance with all legal requirements (including timely
filings, proofs and payments of fees) and is valid and enforceable, except where the failure to be in compliance or to be valid and enforceable has not and could not reasonably be expected to have a Material Adverse Effect on the Company and its
Subsidiaries taken as a whole. No Intellectual Property of the Company or its Subsidiaries which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed
to be conducted has been or is now involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no such action is threatened. No patent of the Company or its Subsidiaries has been or is now involved in any interference,
reissue, re-examination or opposition proceeding. 
  
 (b) All of the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are necessary for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as
currently conducted or as currently proposed to be conducted to which the Company or any Subsidiary is a party or by which any of their assets are bound (other than generally commercially available, non-custom, off-the-shelf software application
programs having a retail acquisition price of less than $10,000 

  

 -11- 

 
per license) (collectively, “License Agreements”) are valid and binding obligations of the Company or its Subsidiaries that are parties thereto
and, to the Company’s Knowledge, the other parties thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or
other similar laws affecting the enforcement of creditors’ rights generally, and there exists no event or condition which will result in a material violation or breach of or constitute (with or without due notice or lapse of time or both) a
default by the Company or any of its Subsidiaries under any such License Agreement. 
  
 (c) The Company and its Subsidiaries own or have the valid right to use all of the Intellectual Property that is necessary for the conduct
of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted and for the ownership, maintenance and operation of the Company’s and its Subsidiaries’
properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary course of the
Company’s and its Subsidiaries’ businesses. The Company and its Subsidiaries have a valid and enforceable right to use all third party Intellectual Property and Confidential Information used or held for use in the respective businesses of
the Company and its Subsidiaries. 
  
 (d) The
conduct of the Company’s and its Subsidiaries’ businesses as currently conducted does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property rights of any third party or any
confidentiality obligation owed to a third party, and, to the Company’s Knowledge, the Intellectual Property and Confidential Information of the Company and its Subsidiaries which are necessary for the conduct of Company’s and each of its
Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge,
threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Intellectual Property or Confidential Information of the Company and its Subsidiaries and the Company’s and its
Subsidiaries’ use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there is no valid basis for the same. 
  
 (e) The consummation of the transactions contemplated hereby and by the other Transaction Documents will not
result in the alteration, loss, impairment of or restriction on the Company’s or any of its Subsidiaries’ ownership or right to use any of the Intellectual Property or Confidential Information which is necessary for the conduct of
Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted. 
  
 (f) The Company and its Subsidiaries have taken reasonable steps to protect the Company’s and its Subsidiaries’ rights in their
Intellectual Property and Confidential Information. Each employee, consultant and contractor who has had access to Confidential Information which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses
as currently conducted or as currently proposed to be conducted has 

  

 -12- 

 
executed an agreement to maintain the confidentiality of such Confidential Information and has executed appropriate agreements that are substantially
consistent with the Company’s standard forms thereof. Except under confidentiality obligations, there has been no material disclosure of any of the Company’s or its Subsidiaries’ Confidential Information to any third party.

  
 4.16 Environmental Matters. Neither
the Company nor any Subsidiary is in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or
relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), owns or operates any real property contaminated with any substance that is subject to any
Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, and is subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim has had or could
reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the Company’s Knowledge, threatened investigation that might lead to such a claim. 
  
 4.17 Litigation. Except as described on Schedule
4.17, there are no pending actions, suits or proceedings against or affecting the Company, its Subsidiaries or any of its or their properties involving an amount in controversy in excess of $175,000; and to the Company’s Knowledge, no such
actions, suits or proceedings are threatened or contemplated. 
  
 4.18 Financial Statements. Except as described on Schedule 4.18, the financial statements included in each SEC Filing, and the draft financial statements for the fiscal year ended July 3, 2004 (included
in the Draft 10-K), and the quarter ended October 2, 2004 (attached hereto as Exhibit H) (the “Interim Financial Statements”), present fairly, in all material respects, the consolidated financial position of the Company as of the
dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis
(“GAAP”) (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial statements of the Company
included in the SEC Filings filed prior to the date hereof, the Interim Financial Statements or as described on Schedule 4.18, neither the Company nor any of its Subsidiaries has incurred any liabilities, contingent or otherwise, except those
incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or could reasonably be expected to have a
Material Adverse Effect. 
  
 4.19 Insurance
Coverage. The Company and each Subsidiary maintains in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company and each
Subsidiary, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to insure. 
  

 -13- 

 4.20 Compliance with Nasdaq Continued Listing Requirements. Except as described in
Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. Except as described in Schedule 4.20, there are no proceedings pending or, to the Company’s Knowledge, threatened against the
Company relating to the continued listing of the Company’s Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any basis for, the delisting of the Common Stock from Nasdaq. Except
as described in Schedule 4.20, the Company is in material compliance with NASD rules and regulations applicable to the Company. 
  
 4.21 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than as
described in Schedule 4.21. 
  
 4.22 No
Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or
sale of any of the Securities. 
  
 4.23 No
Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under
circumstances that would adversely affect reliance by the Company on Section 4(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the Securities under the 1933 Act. 
  
 4.24 Private Placement. Assuming the truth and
accuracy of the Investors’ representations set forth in Section 5 of this Agreement, the offer and sale of the Securities to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act. 
  
 4.25 Questionable Payments. Neither the
Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of their respective current or former stockholders, directors, officers, employees, agents or other Persons acting on behalf of the Company or any Subsidiary, has on
behalf of the Company or any Subsidiary or in connection with their respective businesses: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct
or indirect unlawful payments to any governmental officials or employees from corporate funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious entries on the books
and records of the Company or any Subsidiary; or (e) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature. 
  
 4.26 Transactions with Affiliates. Except as disclosed in the SEC Filings or as disclosed on
Schedule 4.26, none of the officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any 

  

 -14- 

 
transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as employees, officers and
directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or
such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 
  
 4.27 Internal Controls. Except as described in
Schedule 4.27, the Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the Company. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to
provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in Schedule 4.27, the Company has established disclosure controls and procedures (as defined in
1934 Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including the Subsidiaries, is made known to the certifying officers by others within
those entities, particularly during the period in which the Company’s most recently filed period report under the 1934 Act, as the case may be, is being prepared. Except as described in Schedule 4.27, the Company’s certifying
officers have evaluated the effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic report under the 1934 Act (such date, the “Evaluation Date”). Except as
described in Schedule 4.27, the Company presented in its most recently filed periodic report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Except as described in Schedule 4.27, since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K)
or, to the Company’s Knowledge, in other factors that could significantly affect the Company’s internal controls. The Company maintains and will continue to maintain a standard system of accounting established and administered in
accordance with GAAP and the applicable requirements of the 1934 Act. 
  
 4.28 Disclosures. Prior to the Effectiveness Deadline, the Company shall take such actions as may be necessary so that at the Effectiveness Deadline, neither the Company nor any Person acting on its behalf will
have provided the Investors or their agents or counsel with any information that continues to constitute or might constitute material, non-public information. The written materials delivered to the Investors in connection with the transactions
contemplated by the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made,
not misleading. 
  

 -15- 

 4.29 Effect of Consents and Waivers. Upon the execution and delivery of the
Consents and Waivers by the holders of Senior Debt, no event of default or event which, with the giving of notice, the lapse of time or both, would become an event of default shall exist under any agreement, instrument or other document evidencing
Senior Debt or relating thereto. 
  
 4.30
Effect of Voting Agreements. The terms of the Voting Agreements are sufficient to effect the conversion of all outstanding shares of all classes and series of the Company’s preferred stock (or any rights to receive any such preferred
stock) into shares of Common Stock in accordance with the terms of the Company’s Certificate of Incorporation (or any agreement evidencing such right to receive preferred stock), subject only to the approval of the Proposals and the filing of
an amendment to the Certificate of Incorporation to effect the Capital Increase (as defined in Section 7.9). 
  
 4.31 Unqualified Audit Opinion. The Company has been advised by its independent public accountant that upon the Closing of the sale
of the Notes and the effectiveness of the Consents and Waivers, the accountants will issue an opinion on the Company’s financial statements for the year ended December 31, 2003 that will not contain an explanatory paragraph relating to the
Company’s ability to continue as a going concern. 
  
 5.
Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and warrants to the Company that: 
  

5.1 Organization and Existence. Such Investor is a validly existing corporation, limited partnership or limited liability
company and has all requisite corporate, partnership or limited liability company power and authority to invest in the Securities pursuant to this Agreement. 
  

5.2 Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor
is a party have been duly authorized and will each constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with their respective terms, subject to (i) bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and (ii) laws relating to the availability of specific performance, injunctive relief or other equitable
remedies. 
  
 5.3 Purchase Entirely for
Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933
Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise
dispose of all or any part of such Securities in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of
time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 
  

 -16- 

 5.4 Investment Experience. Such Investor acknowledges that it can bear the
economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 
  
 5.5 Disclosure of Information. Such Investor has had
an opportunity to receive all information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities. Such
Investor acknowledges receipt of copies of the SEC Filings. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, amend or affect such Investor’s right to rely on the Company’s
representations and warranties contained in this Agreement. 
  
 5.6 Restricted Securities. Such Investor understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from
the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. 
  
 5.7 Legends. It is understood that, except as
provided below, certificates evidencing the Securities may bear the following or any similar legend: 
  
 (a) “The securities represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant to
the Securities Act of 1933, as amended, (ii) such securities are sold pursuant to Rule 144(k), or (iii) the Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under
the Securities Act of 1933.” 
  
 (b) If
required by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such state authority. 
  
 5.8 Accredited Investor. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the
1933 Act. 
  
 5.9 No General Solicitation.
Such Investor did not learn of the investment in the Securities as a result of any public advertising or general solicitation. 
  
 5.10 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor. 
  
 5.11 Prohibited Transactions. During the last thirty
(30) days prior to the date hereof, neither such Investor nor any Affiliate of such Investor, which (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to such Investor’s 

  

 -17- 

 
investments or trading or information concerning such Investor’s investments, including in respect of the Securities, or (z) is subject to such
Investor’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”), has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the box,
established any “put equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock
or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position in the Securities (each, a “Prohibited Transaction”). Prior to the
earliest to occur of (i) the termination of this Agreement, (ii) the Effective Date or (iii) 90 days after the Closing Date, such Investor shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in a Prohibited
Transaction. Such Investor acknowledges that the representations, warranties and covenants contained in this Section 5.11 are being made for the benefit of the Investors as well as the Company and that each of the other Investors shall have an
independent right to assert any claims against such Investor arising out of any breach or violation of the provisions of this Section 5.11. 
  
 6. Conditions to Closing. 
  
 6.1 Conditions to the Investors’ Obligations. The obligation of each Investor to purchase the Notes at the Closing is subject
to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 
  
 (a) The representations and warranties made by the Company in Section 4 hereof qualified as to materiality
shall be true and correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of
such earlier date, and, the representations and warranties made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct in all material respects at all times prior to and on the Closing Date, except to the extent
any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. The Company shall have performed in all material
respects all obligations and conditions herein required to be performed or observed by it on or prior to the Closing Date. 
  
 (b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers (other than the approval of the
Proposals by its stockholders in accordance with applicable law and the applicable requirements of any stock exchange or market on which the Common Stock is traded or quoted) necessary or appropriate for consummation of the purchase and sale of the
Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 
  
 (c) The Company shall have executed and delivered the Registration Rights Agreement. 
  

 -18- 

 (d) [Intentionally Omitted] 
  
 (e) The Company shall have received confirmation from Nasdaq
to the effect that the issuance and sale of the Notes as contemplated hereby will not require stockholder approval pursuant to the requirements of Nasdaq Marketplace Rule 4350(i). 
  
 (f) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or
magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the
consummation of the transactions contemplated hereby or in the other Transaction Documents. 
  
 (g) The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief
Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e), (f) and (j) of this Section 6.1. 
  
 (h) The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary,
dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other Transaction Documents (including the Reverse Split) and the issuance of
the Securities, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the
Company. 
  
 (i) The Investors shall have
received an opinion of counsel to the Company, dated as of the Closing Date, in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request. 
  
 (j) No stop order or suspension of trading shall have been
imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. 
  
 (k) [Intentionally Omitted] 
  
 (l) The holders of the Senior Debt shall have executed and delivered the Consents and Waivers. 
  
 (m) [Intentionally Omitted] 
  
 (n) The Company and the stockholders listed on Schedule
6.1 hereto shall have executed and delivered one or more Voting Agreements providing for, among other things, the conversion of all issued and outstanding shares of the Company’s preferred stock, par value $0.004 per share, into Common
Stock upon the approval of the Proposals on the terms described therein. 
  

 -19- 

 (o) [Intentionally Omitted] 
  
 6.2 Conditions to Obligations of the Company. The
Company’s obligation to sell and issue the Notes at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

 
 (a) The representations and warranties made by the
Investors in Section 5 hereof, other than the representations and warranties contained in Sections 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 (the “Investment Representations”), shall be true and correct in all material respects when made, and
shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investment Representations shall be true and correct in all respects when made, and shall be
true and correct in all respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investors shall have performed in all material respects all obligations and conditions herein required to be
performed or observed by them on or prior to the Closing Date. 
  
 (b) The Investors shall have executed and delivered the Registration Rights Agreement. 
  
 (c) The Investors shall have delivered the Purchase Price to the Company. 
  
 6.3 Termination of Obligations to Effect Closing; Effects. 
  
 (a) The obligations of the Company, on the one hand, and the
Investors, on the other hand, to effect the Closing shall terminate as follows: 
  
 (i) Upon the mutual written consent of the Company and the Investors; 
  
 (ii) By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of
fulfillment, and shall not have been waived by the Company; 
  
 (iii) By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or 
  
 (iv) By either the Company or any Investor (with respect to
itself only) if the Closing has not occurred on or prior to                         ; 
  
 provided, however, that, except in the case of clause (i) above, the party seeking to
terminate its obligation to effect the Closing shall not then be in breach of any of its representations, 

  

 -20- 

 
warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving
rise to such party’s seeking to terminate its obligation to effect the Closing. 
  
 (b) In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3,
written notice thereof shall forthwith be given to the other Investors and the other Investors shall have the right to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors. Nothing in this
Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by
any other party of its obligations under this Agreement or the other Transaction Documents. 
  
 7. Covenants and Agreements of the Company. 
  
 7.1 Reservation of Common Stock. Following stockholder adoption of the Proposals described in Section 7.9 and the effectiveness of
the amendments to the Company’s Certificate of Incorporation contemplated by the adoption of the Proposals, the Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the
purpose of providing for the issuance of the Conversion Shares, such number of shares of Common Stock as shall from time to time equal the number of Conversion Shares issuable pursuant to the Shares and the PIK Shares. 
  
 7.2 Reports. The Company will furnish to such
Investors and/or their assignees such information relating to the Company and its Subsidiaries as from time to time may reasonably be requested by such Investors and/or their assignees; provided, however, that the Company shall not disclose material
nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors,
such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the
Company with respect thereto. 
  
 7.3 No
Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction
Documents. 
  
 7.4 Insurance. The Company
shall not materially reduce the insurance coverages described in Section 4.19. 
  
 7.5 Compliance with Laws. The Company will comply in all material respects with all applicable laws, rules, regulations, orders and
decrees of all governmental authorities. 
  
 7.6
Listing of Underlying Shares and Related Matters. Promptly following the date hereof, the Company shall take all necessary action to cause the Conversion Shares to be 

  

 -21- 

 
listed on the Nasdaq SmallCap Market no later than the Conversion Date. Further, if the Company applies to have its Common Stock or other securities traded
on any other principal stock exchange or market, it shall include in such application the Conversion Shares and will take such other action as is necessary to cause such Common Stock to be so listed. The Company will use commercially reasonable
efforts to continue the listing and trading of its Common Stock on the Nasdaq Stock Market (including effecting the Reverse Split promptly following stockholder approval of the Proposals) and, in accordance, therewith, will use commercially
reasonable efforts to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable. 
  
 7.7 Termination of Covenants. The provisions of Sections 7.2 through 7.5 shall terminate and be of no
further force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering the Registrable Securities (as such term is defined in the
Registration Rights Agreement) shall terminate. 
  
 7.8 Removal of Legends. Upon the earlier of (i) registration for resale pursuant to the Registration Rights Agreement and receipt by the Company of the Investor’s written confirmation that such Securities will not be disposed of
except in compliance with the prospectus delivery requirements of the 1933 Act or (ii) Rule 144(k) becoming available the Company shall, upon an Investor’s written request, promptly cause certificates evidencing the Investor’s Securities
to be replaced with certificates which do not bear such restrictive legends, and Shares subsequently issued upon due conversion of the Notes and Conversion Shares subsequently issued upon due conversion of the Shares or the PIK Shares shall not bear
such restrictive legends provided the provisions of either clause (i) or clause (ii) above, as applicable, are satisfied with respect thereto. When the Company is required to cause unlegended certificates to replace previously issued legended
certificates, if unlegended certificates are not delivered to an Investor within three (3) Business Days of submission by that Investor of legended certificate(s) to the Company’s transfer agent together with a representation letter in
customary form, the Company shall be liable to the Investor for liquidated damages in an amount equal to 1% of the aggregate purchase price of the Securities evidenced by such certificate(s) for each thirty (30) day period (or portion thereof)
beyond such three (3) Business Day that the unlegended certificates have not been so delivered. 
  
 7.9 Proxy Statement; Stockholders Meeting. (a) Promptly following the execution and delivery of this Agreement the Company shall
take all action necessary to call a meeting of its stockholders (the “Stockholders Meeting”), which shall occur not later than April 30, 2005 (the “Stockholders Meeting Deadline”), for the purpose of seeking approval of the
Company’s stockholders for (i) the issuance and sale to the Investors of the Securities and (ii), the Reverse Split, (iii) the adoption of the Stock Option Plan (as defined below) and (iv) the increase in the Company’s capital stock in at
least an amount as will allow the Company to satisfy its obligations under the Transaction Documents (including the conversion of the Notes and the Series M Preferred Stock) and under any other agreements or arrangements entered into by the Company
prior to the date hereof (the “Capital Increase”) (collectively, the “Proposals”). In connection therewith, the Company will promptly prepare and file with the SEC proxy materials (including a proxy statement and form of proxy)
for use at the Stockholders Meeting 

  

 -22- 

 
and, after receiving and promptly responding to any comments of the SEC thereon, shall promptly mail such proxy materials to the stockholders of the Company.
Each Investor shall promptly furnish in writing to the Company such information relating to such Investor and its investment in the Company as the Company may reasonably request for inclusion in the Proxy Statement. The Company will comply with
Section 14(a) of the 1934 Act and the rules promulgated thereunder in relation to any proxy statement (as amended or supplemented, the “Proxy Statement”) and any form of proxy to be sent to the stockholders of the Company in connection
with the Stockholders Meeting, and the Proxy Statement shall not, on the date that the Proxy Statement (or any amendment thereof or supplement thereto) is first mailed to stockholders or at the time of the Stockholders Meeting, contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein not false or misleading, or omit to state any material fact necessary to correct any statement in any earlier communication with
respect to the solicitation of proxies or the Stockholders Meeting which has become false or misleading. If the Company should discover at any time prior to the Stockholders Meeting, any event relating to the Company or any of its Subsidiaries or
any of their respective affiliates, officers or directors that is required to be set forth in a supplement or amendment to the Proxy Statement, in addition to the Company’s obligations under the 1934 Act, the Company will promptly inform the
Investors thereof. 
  
 (b) Subject to their
fiduciary obligations under applicable law (as determined in good faith by the Company’s Board of Directors after consultation with the Company’s outside counsel), the Company’s Board of Directors shall recommend to the Company’s
stockholders (and, subject to their fiduciary obligations, not revoke or amend such recommendation) that the stockholders vote in favor of the Proposals and shall cause the Company to take all commercially reasonable action to solicit the approval
of the stockholders for the Proposals. Whether or not the Company’s Board of Directors determines at any time after the date hereof that, due to its fiduciary duties, it must revoke or amend its recommendation to the Company’s
stockholders, the Company shall be required to, and will take, in accordance with applicable law and its Certificate of Incorporation and By-laws, all action necessary to convene the Stockholders Meeting as promptly as practicable, but no later than
the Stockholders Meeting Deadline, to consider and vote upon the approval of the Proposals. 
  
 7.10 Prohibited Sales. Except as provided in Section 3(b) or as described on Schedule 7.10, from and after the Closing Date
and continuing for a period until the earlier to occur of (i) three (3) years thereafter, or (ii) the date on which the Investors beneficially own in the aggregate less than 10% of the Company’s outstanding Common Stock, the Company will not,
and will cause its Subsidiaries not to, issue any: 
  

	 	(i)	shares of preferred stock which are convertible into shares of Common Stock other than on a conversion ratio which is fixed, except in the case of normal adjustments which may
include customary anti-dilution provisions, among other things, but which shall not include in any case any adjustment in the conversion ratio of such shares of Preferred Stock as a result of the market price of the Common Stock after the date of
closing of the issuance of such shares of preferred stock; 

  

 -23- 

	 	(ii)	convertible debt in the Company which is convertible into shares of Common Stock of the Company other than on a conversion ratio which is fixed, except in the case of normal
adjustments which may include customary anti-dilution provisions, among other things, but which shall not include in any case any adjustment in the conversion ratio of such convertible debt based on the market price of the Common Stock after the
date of closing of the issuance of such convertible debt; or 

  

	 	(iii)	shares of Common Stock of the Company other than for a fixed price at the time of issuance of such shares of Common Stock, except in the case of normal adjustments which may include
customary anti-dilution provisions, among other things, but which shall not include in any case any adjustments to the issued shares of Common Stock which require the issuance of additional shares of Common Stock during that time based on the market
price of the Common Stock. 

  
 7.11
Right of First Refusal on Future Financings. From the date hereof until one year after the Closing Date, upon any financing by the Company of its Common Stock or Common Stock Equivalents (a “Subsequent Financing”), each Investor
shall have the right to participate in such Subsequent Financing as described herein. At least five (5) Business Days prior to the closing of the Subsequent Financing, the Company shall deliver to each Investor a written notice of its intention to
effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall ask such Investor if it wants to review the details of such financing (such additional notice, a “Subsequent Financing Notice”). Upon the request of an
Investor, and only upon a request by such Investor, for a Subsequent Financing Notice, the Company shall promptly, but no later than one Business Day after such request, deliver a Subsequent Financing Notice to such Investor. The Subsequent
Financing Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder, the Person with whom such Subsequent Financing is proposed to be effected, and attached to
which shall be a term sheet or similar document relating thereto. Each Investor shall notify the Company by 6:30 p.m. (New York City time) on the fifth (5th) Business Day after their receipt of the Subsequent Financing Notice of its willingness to provide the Subsequent Financing on the terms described in the Subsequent Financing Notice, subject to
completion of mutually acceptable documentation. If one or more Investors shall fail to so notify the Company of their willingness to participate in the Subsequent Financing, the Investors agreeing to participate in the Subsequent Financing (the
“Participating Investors”) shall have the right to provide all of the Subsequent Financing. If one or more Investors fail to notify the Company of their willingness to provide all of the Subsequent Financing and the Participating Investors
do not agree to provide all of the Subsequent Financing, the Company may effect the remaining portion of such Subsequent Financing on the terms and to the Persons set forth in the Subsequent Financing Notice; provided that the Company must provide
the Investors with a second Subsequent Financing Notice, and the Investors will again have the right of first refusal set forth above in this Section 7.11, if the Subsequent Financing subject to the initial Subsequent Financing Notice is not
consummated for any reason on the terms set forth in such Subsequent Financing Notice within 60 Business Days after the date of the initial Subsequent Financing Notice with the Person identified in the Subsequent Financing Notice. In the event the
Company receives responses to Subsequent Financing Notices from Investors seeking to purchase more than the 

  

 -24- 

 
financing sought by the Company in the Subsequent Financing such Investors shall have the right to purchase their Pro Rata Portion (as defined below) of the
Common Stock or Common Stock Equivalents to be issued in such Subsequent Financing. “Pro Rata Portion” is the ratio of (x) the amount invested by such Investor pursuant to this Agreement (the “Subscription Amount”) and (y) the
aggregate sum of all of the Subscription Amounts. Notwithstanding the foregoing, this Section 7.11 shall not apply in respect of the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors of the Company
pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities
upon the exercise of or conversion of any convertible securities, options or warrants issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement and (c) securities to a
strategic partner in a transaction, the primary purpose of which is not the raising of capital and (d) securities to a lender in connection with the provision of credit to the Company. 
  
 7.12 Conversion of Notes. The Company shall use its commercially reasonable efforts to satisfy the
conditions to the conversion of the Notes as promptly as practicable after the date hereof. Without limiting the generality of the foregoing, within two Business Days of the stockholder approval of the Proposals, the Company will file the
Certificate of Designations and an amendment to the Company’s Certificate of Incorporation to effect the Capital Increase and the Reverse Split. 
  
 7.13 Stock Grants and Awards. The Company shall have the right to grant stock options, restricted shares, performance units and
other awards (collectively “Awards”) only to directors, officers, employees and independent contractors and only under a stock award plan adopted by the Board of Directors of the Company and approved by the Company’s stockholders
(such plan, the “Stock Option Plan”). The Stock Option Plan shall provide for the granting of Awards up to a specific number of shares of Common Stock (subject to customary anti-dilution adjustments) which in the aggregate shall not exceed
10.3% of the Company’s Common Stock (less the number of shares of Common Stock available for grant under any existing stock option, stock compensation or stock purchase plan), determined on a fully diluted basis assuming the exercise,
conversion or exchange of all securities exercisable, convertible or exchangeable for or into shares of Common Stock; provided, however, that all securities having an exercise price, conversion price or exchange price greater than $0.51 per share
shall be excluded from such calculation) and shall not contain any “evergreen” or formula provisions increasing the number of shares of Common Stock available for grant thereunder (other than customary anti-dilution adjustments). Such
Awards shall have an exercise price of not less than the effective price per share of Common Stock acquired by the Investors hereunder (assuming immediate conversion of the Notes into Series M Preferred Stock and the immediate conversion of the
Series M Preferred Stock into Common Stock) and shall be granted subject to the terms and conditions summarized on Schedule 7.13 hereto. 
  

 -25- 

 8. Survival and Indemnification. 
  
 8.1 Survival. The representations, warranties, covenants and agreements contained in this Agreement
shall survive the Closing of the transactions contemplated by this Agreement. 
  
 8.2 Indemnification. The Company agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, employees and agents from and against any and all losses,
claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or
threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the
Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person. 
  
 8.3 Conduct of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”) of
notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity may be sought pursuant to Section 8.2, such Indemnified Person shall
promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided,
however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is materially prejudiced by such failure to notify. In any such
proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually
agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.
The Company shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff, the
Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Person, which
consent shall not be unreasonably withheld, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder
by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding. 
  
 9. Miscellaneous. 
  
 9.1 Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company
or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Securities in a 

  

 -26- 

 
private transaction without the prior written consent of the Company or the other Investors, after notice duly given by such Investor to the Company and the
other Investors, provided, that no such assignment or obligation shall affect the obligations of such Investor hereunder. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and
assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement. 
  
 9.2 Counterparts; Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This
Agreement may also be executed via facsimile, which shall be deemed an original. 
  
 9.3 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
  
 9.4 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal
delivery, then such notice shall be deemed given upon such delivery, (ii) if given by telex or telecopier, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be
deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such
notice shall be deemed given one business day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance
written notice to the other party: 
  
 If to the Company:

  
 Velocity Express Corporation 
 One Morningside Drive North 
 Building B
— Suite 300 
 Westport, CT 06880 
 Attention: 
 Fax: 
  
 With a copy to: 
  
 Dorsey & Whitney LLP 
 Fifty South
Sixth Street, Suite 1500 
 Minneapolis, MN 55402 
 Attention: Jonathan B. Abram, Esq. 
 Fax: (612) 340-2868 
  

 -27- 

 If to the Investors: 
  
 to the addresses set forth on the signature pages hereto. 
  
 9.5 Expenses. The parties hereto shall pay their own costs and expenses in connection herewith,
except that the Company shall pay the reasonable fees and expenses of counsel to the Investors, not to exceed $100,000. Such expenses shall be paid not later than the Closing. The Company shall reimburse the Investors upon demand for all reasonable
out-of-pocket expenses incurred by the Investors, including without limitation reimbursement of attorneys’ fees and disbursements, in connection with any amendment, modification or waiver of this Agreement or the other Transaction Documents. In
the event that legal proceedings are commenced by any party to this Agreement against another party to this Agreement in connection with this Agreement or the other Transaction Documents, the party or parties which do not prevail in such proceedings
shall severally, but not jointly, pay their pro rata share of the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing party in such proceedings. 
  
 9.6 Amendments and Waivers. Any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors. Any
amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all such Securities, and the Company. 
  
 9.7 Publicity. Except as set forth below, no public
release or announcement concerning the transactions contemplated hereby shall be issued by the Company or the Investors without the prior consent of the Company (in the case of a release or announcement by the Investors) or the Investors (in the
case of a release or announcement by the Company) (which consents shall not be unreasonably withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities
market, in which case the Company or the Investors, as the case may be, shall allow the Investors or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in
advance of such issuance. By 8:30 a.m. (New York City time) on the trading day immediately following the Closing Date, the Company shall issue a press release disclosing the consummation of the transactions contemplated by this Agreement. No later
than the third trading day following the Closing Date, the Company will file a Current Report on Form 8-K attaching the press release described in the foregoing sentence as well as copies of the Transaction Documents. In addition, the Company will
make such other filings and notices in the manner and time required by the SEC or Nasdaq. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Investor, or include the name of any Investor in any filing with the SEC
(other than the Registration Statement and any exhibits to filings made in respect of this transaction in accordance with periodic filing requirements under the 1934 Act) or any regulatory agency or Nasdaq, without the prior written consent of such
Investor, except to the extent such disclosure is 

  

 -28- 

 
required by law or trading market regulations, in which case the Company shall provide the Investors with prior notice of such disclosure. 
  
 9.8 Severability. Any provision of this Agreement
that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were
written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent
permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 
  
 9.9 Entire Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction Documents
constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter
hereof and thereof. 
  
 9.10 Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the
agreements herein contained. 
  
 9.11
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of
the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the
same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each
party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
  
 9.12 Independent Nature of Investors’ Obligations
and Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other
Investor under any Transaction Document. The decision of each Investor to purchase Securities pursuant to the Transaction Documents has been made by such 

  

 -29- 

 
Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto,
shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of
such Investor in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the
Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. 
  
 [signature page follows] 
  

 -30- 

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to
execute this Agreement as of the date first above written. 
  

									
	The Company:	 	 	 	VELOCITY EXPRESS CORPORATION
					
	 	 	 	 	 	 	 By:
	 	 
	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 

  

 -31- 

									
	The Investors:	 	 	 	 SPECIAL SITUATIONS FUND III, L.P.

					
	 	 	 	 	 	 	 By:
	 	 
	 	 	 	 	 	 	 Name:
	 	 Austin W. Marxe

	 	 	 	 	 	 	 Title:
	 	 General Partner

  
 Aggregate Purchase Price: $2,250,000

 Principal Amount of Notes: $2,250,000 
  
 Address for Notice: 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  

									
	 	 	 	 	SPECIAL SITUATIONS CAYMAN FUND, L.P.
					
	 	 	 	 	 	 	 By:
	 	 
	 	 	 	 	 	 	 Name:
	 	 Austin W. Marxe

	 	 	 	 	 	 	 Title:
	 	 General Partner

  
 Aggregate Purchase Price: $750,000

 Principal Amount of Notes: $750,000 
  
 Address for Notice: 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  

 -32- 

			
	SPECIAL SITUATIONS PRIVATE EQUITY FUND, L.P.
		
	By:	 	 
	Name:	 	Austin W. Marxe
	Title:	 	General Partner

  
 Aggregate Purchase Price:
$3,000,000 
 Principal Amount of Notes: $3,000,000 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  

 -33- 

			
	SCORPION CAPITAL PARTNERS, L.P.
		
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

  
 Aggregate Purchase Price:
$5,000,000 
 Principal Amount of Notes: $5,000,000 
  
 Address for Notice: 
  
 245 Fifth Avenue, 25th Floor 
 New York, NY 10016 
 (212) 213-9190 
 (212) 213-9607 fax 
  

			
	SCORPION ACQUISITION, LLC
		
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

  
 Aggregate Purchase Price:
$800,000 
 Principal Amount of Notes: $800,000 
  
 Address for Notice: 
  
 245 Fifth Avenue, 25th Floor 
 New York, NY 10016 
 (212) 213-9190 
 (212) 213-9607 fax 
  

 -34- 

			
	 PEQUOT SCOUT FUND, L.P.

	 By Pequot Capital Management, Inc.
 as
Investment Manager

		
	 By:
	 	 
	 Name:
	 	 Aryeh Davis

	 Title:
	 	 General Counsel

  
 Aggregate Purchase Price:
$2,907,600 
 Principal Amount of Notes: $2,907,600 
  
 Address for Notice: 
  

			
	PEQUOT NAVIGATOR ONSHORE FUND, L.P.
	 By Pequot Capital Management, Inc.
 as
Investment Manager

		
	 By:
	 	 
	 Name:
	 	 Aryeh Davis

	 Title:
	 	 General Counsel

  
 Aggregate Purchase Price:
$1,724,700 
 Principal Amount of Notes: $1,724,700 
  
 Address for Notice: 
  

			
	PEQUOT NAVIGATOR OFFSHORE FUND, INC.
	 By Pequot Capital Management, Inc.
 as
Investment Advisor

		
	 By:
	 	 
	 Name:
	 	 Aryeh Davis

	 Title:
	 	 General Counsel

  

 -35- 

 Aggregate Purchase Price: $1,266,700 
 Principal Amount of Notes: $1,266,700 
  
 Address for Notice: 

 

			
	 PREMIUM SERIES PCC LIMITED - CELL 33

		
	By:	 	 
	 Name: Michael Griffin

	 Title: Authorized Signatory

  
 Aggregate Purchase Price:
$101,000 
 Principal Amount of Notes: $101,000 
  
 Address for Notice: 
  

 -36- 

			
	 TH LEE PUTNAM VENTURES, L.P.

		
	By:	 	 TH Lee Putnam Fund Advisors, L.P.,
 its General Partner

		
	 By:
	 	 TH Lee Putnam Fund Advisors, LLC,
 its General Partner

  

			
		
	By:	 	 
	 Name: James Brown

	 Title: Managing Director

  
 Aggregate Purchase Price:
$965,392 
 Principal Amount of Notes: $965,392 
  
 Address for Notice: 
  

			
	 TH LEE PUTNAM PARALLEL VENTURES, L.P.

		
	By:	 	 TH Lee Putnam Fund Advisors, L.P.,
 its General Partner

		
	 By:
	 	 TH Lee Putnam Fund Advisors, LLC,
 its General Partner

  

			
		
	By:	 	 
	 Name: James Brown

	 Title: Managing Director

  
 Aggregate Purchase Price:
$706,204 
 Principal Amount of Notes: $706,204 
  

 -37- 

 Address for Notice: 
  

			
	THLi COINVESTMENT PARTNERS, LLC
		
	By:	 	 TH Lee Putnam Fund Advisors, L.P.,
its General Partner

		
	By:	 	 TH Lee Putnam Fund Advisors, LLC,
its General Partner

		
	By:	 	 
	 Name:
	 	 James Brown

	 Title:
	 	 Managing Director

  
 Aggregate Purchase Price:
$56,531 
 Principal Amount of Notes: $56,531 
  
 Address for Notice: 
  

			
	 BLUE STAR I, LLC

		
	By:	 	 
	 Name:
	 	 Thomas H. Lee

	 Title:
	 	 Managing Member

  
 Aggregate Purchase Price:
$21,873 
 Principal Amount of Notes: $21,873 
  
 Address for Notice: 
  

 -38- 

	
	
	 
	Jack Duffy

 Aggregate Purchase Price: $250,000 
 Principal Amount of Notes: $250,000 
  
 Address
for Notice: 
  

	
	
	 
	William Kingston

 Aggregate Purchase Price: $250,000 
 Principal Amount of Notes: $250,000 
  
 Address
for Notice: 
  

	
	
	 
	Dolph DiBiaso

  
 Aggregate Purchase Price:
$250,000 
 Principal Amount of Notes: $250,000 
  
 Address for Notice: 
  

 -39- 

	
	 
	
	 
	Vincent Wasik

  
 Aggregate Purchase Price:
$500,000 
 Principal Amount of Notes: $500,000 
  
 Address for Notice: 
  

 -40- 

			
	PALM BEACH OVERSEAS INVESTORS, LIMITED
		
	By:	 	 
	 	 	 Name: Mark Kesselman

	 	 	 Title: Authorized Signatory

  
 Aggregate Purchase Price:
$200,000 
 Principal Amount of Notes: $200,000 
  
 Address for Notice: 
  

 -41-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]